Can You Have Both PCOS and Endometriosis?

The Short Answer: Yes, You Can Have Both

PCOS and endometriosis are not mutually exclusive. They arise from different pathophysiological pathways, affect different tissue types, and respond to different hormonal signals. Yet they share enough biological ground that overlap is more common than most clinicians once assumed.

What the Data Shows

A 2015 cross-sectional analysis published in Fertility and Sterility (N=680 women undergoing laparoscopy) found that 19% of participants with confirmed PCOS also had surgically verified endometriosis [1]. A larger Danish registry-based cohort study (N=18,112) published in Human Reproduction in 2017 reported that women with PCOS had a significantly elevated risk of subsequent endometriosis diagnosis compared to age-matched controls (hazard ratio 1.59, 95% CI 1.37 to 1.84) [2].

Why the Overlap Gets Missed

Part of the problem is diagnostic framing. PCOS is typically identified through blood work, ultrasound, and the Rotterdam criteria. Endometriosis requires surgical confirmation via laparoscopy, though clinical suspicion can be raised by history and imaging. When a patient already carries a PCOS diagnosis, pelvic pain may be attributed to ovarian cysts or anovulatory cycles rather than prompting investigation for endometrial implants [3]. The reverse also happens: a patient with known endometriosis may have irregular cycles written off as a byproduct of their existing diagnosis.

"The assumption that these two conditions somehow cancel each other out is not supported by the evidence," noted Dr. Hugh Taylor, Chair of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine, in a 2021 editorial in the Journal of Clinical Endocrinology & Metabolism [4]. That framing is slowly shifting, but diagnostic delay persists.

Understanding PCOS and Endometriosis Separately

Before examining the overlap, it helps to understand what each condition does on its own. They affect different tissues, respond to different hormones, and produce distinct (though sometimes overlapping) symptom profiles.

PCOS: An Androgen-Driven Syndrome

PCOS is a syndrome defined by the Rotterdam criteria: at least two of three features must be present. Those features are oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound [5]. Insulin resistance accompanies approximately 70% of cases regardless of body mass index [6]. The World Health Organization estimates PCOS affects 8 to 13% of reproductive-age women, making it the most common endocrine disorder in this population [7].

Endometriosis: An Estrogen-Dependent Condition

Endometriosis involves the growth of tissue resembling the endometrial lining outside the uterus. Common sites include the ovaries, fallopian tubes, peritoneum, and cul-de-sac. It is estrogen-dependent, meaning lesion growth is fueled by local and systemic estradiol [8]. The American College of Obstetricians and Gynecologists (ACOG) estimates that endometriosis affects roughly 10% of reproductive-age women [9]. Pain is the hallmark: dysmenorrhea, deep dyspareunia, chronic pelvic pain, and painful bowel movements during menstruation.

Where They Diverge on Paper

PCOS features androgen excess. Endometriosis features estrogen dominance. On the surface, these look like opposite hormonal environments. That apparent contradiction is exactly why clinicians historically assumed co-occurrence was rare. But hormonal environments are not binary, and local tissue-level hormone production can differ substantially from circulating serum levels.

Shared Biological Mechanisms

The overlap between PCOS and endometriosis is not a coincidence. Several biological pathways connect the two conditions, even though their primary hormonal drivers point in different directions.

Chronic Inflammation

Both conditions are characterized by elevated inflammatory markers. Women with PCOS show increased C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) independent of BMI [10]. Endometriosis is defined in part by an inflammatory peritoneal environment with elevated macrophage activity, prostaglandins, and cytokines [8]. This shared inflammatory substrate may create a permissive environment for both conditions to develop.

Oxidative Stress

A 2020 systematic review in Reproductive Biology and Endocrinology found that oxidative stress markers were elevated in both PCOS and endometriosis cohorts, and that the degree of oxidative damage correlated with disease severity in each condition independently [11]. Reactive oxygen species appear to impair oocyte quality in PCOS and promote adhesion formation in endometriosis.

Insulin Resistance and Estrogen Metabolism

Insulin resistance, present in the majority of PCOS cases, increases aromatase activity in adipose tissue. This converts androgens to estrogens at higher-than-normal rates [6]. That locally generated estrogen may contribute to the growth of ectopic endometrial tissue, providing a mechanistic bridge between the hyperandrogenic state of PCOS and the estrogen-dependent growth of endometriosis.

Immune Dysregulation

Natural killer (NK) cell function is altered in both conditions. In endometriosis, reduced NK cell cytotoxicity allows ectopic endometrial cells to survive and implant. In PCOS, NK cell dysfunction has been linked to recurrent pregnancy loss and implantation failure [12]. Whether this reflects a shared upstream immune defect or parallel downstream consequences remains an open question.

How Dual Diagnosis Happens

Getting both conditions diagnosed typically requires a clinician who is actively looking for both. The standard diagnostic pathway for each condition does not automatically screen for the other.

The PCOS-First Pathway

A patient presents with irregular periods, acne, or hirsutism. Labs show elevated free testosterone and DHEA-S. Ultrasound reveals polycystic ovarian morphology. PCOS is diagnosed. If the patient also reports severe dysmenorrhea or chronic pelvic pain, those symptoms should trigger further investigation, but they are sometimes attributed to the PCOS itself.

The 2023 international evidence-based guideline for the assessment and management of PCOS (endorsed by the Endocrine Society) recommends that clinicians "consider endometriosis as a differential or co-existing diagnosis in women with PCOS who report significant pelvic pain, particularly dysmenorrhea that does not respond to first-line treatments" [5].

The Endometriosis-First Pathway

A patient presents with pelvic pain and dysmenorrhea. Laparoscopy confirms endometriosis. If the patient also has irregular cycles, the irregularity may be attributed to endometriosis-related hormonal disruption rather than prompting a separate PCOS evaluation with androgen panels and metabolic workup.

What Comprehensive Evaluation Looks Like

For a patient with suspected dual pathology, the workup should include total and free testosterone, DHEA-S, 17-hydroxyprogesterone (to rule out non-classic congenital adrenal hyperplasia), fasting insulin, fasting glucose, HbA1c, lipid panel, transvaginal ultrasound, and careful symptom mapping for pain patterns [5] [9]. If pain symptoms are prominent and do not respond to hormonal management, laparoscopy remains the definitive diagnostic step for endometriosis.

Treatment When Both Conditions Are Present

Managing PCOS and endometriosis simultaneously requires balancing treatments that may work at cross-purposes. The key is identifying which symptoms are most affecting quality of life and fertility goals.

Hormonal Contraceptives

Combined oral contraceptives (COCs) remain a first-line treatment for both conditions when pregnancy is not desired. COCs suppress ovulation (addressing anovulatory cycles in PCOS), reduce circulating androgens via increased sex hormone-binding globulin (SHBG), and thin the endometrial lining (reducing pain from endometrial implants) [5] [9]. They treat both diagnoses with one medication.

Progestins

Progestin-only therapies, including the levonorgestrel IUD, norethindrone acetate, and dienogest, are effective for endometriosis-related pain [9]. They also provide endometrial protection in PCOS, where unopposed estrogen from anovulatory cycles increases endometrial cancer risk. Dienogest 2 mg daily reduced endometriosis-associated pelvic pain by 47% over 24 weeks in a randomized trial (N=252) published in Fertility and Sterility [13].

Metformin and Insulin Sensitizers

Metformin addresses the insulin resistance component of PCOS. It does not directly treat endometriosis, but by improving insulin sensitivity and reducing circulating insulin, it may lower aromatase-driven estrogen production [6]. Some preclinical data suggest metformin has anti-inflammatory and anti-proliferative effects on endometriotic tissue, though clinical trials in humans are limited [14].

GnRH Agonists and Antagonists

GnRH agonists (leuprolide) and the oral GnRH antagonist elagolix create a hypoestrogenic state that suppresses endometriotic lesion activity. Elagolix 200 mg twice daily reduced dysmenorrhea scores significantly versus placebo in the Elaris EM-I and EM-II trials (N=872 combined) [15]. These agents also suppress ovarian androgen production, which can benefit PCOS-related hyperandrogenism. The tradeoff is menopausal side effects and bone density loss with prolonged use.

Surgical Management

Laparoscopic excision or ablation of endometriotic lesions remains indicated for pain refractory to medical therapy or for diagnosis confirmation. Ovarian drilling for PCOS (a procedure that reduces androgen-producing stromal tissue) has fallen out of favor as medical alternatives have improved, but it is occasionally performed during the same laparoscopic procedure in dual-diagnosis patients [5].

Fertility Implications of Having Both

Both PCOS and endometriosis independently impair fertility, and co-occurrence compounds the challenge. The mechanisms differ, which is actually useful for treatment planning.

How Each Condition Reduces Fertility

PCOS impairs fertility primarily through anovulation. No ovulation means no oocyte for fertilization. This is a timing problem that responds well to ovulation induction. Endometriosis impairs fertility through inflammation, adhesion formation, tubal dysfunction, and reduced oocyte quality [8]. This is a tissue-environment problem that may require surgical correction or assisted reproduction.

Ovulation Induction in Dual-Diagnosis Patients

Letrozole is the first-line ovulation induction agent for PCOS per the 2023 international guideline [5]. It also has theoretical advantages in endometriosis because, as an aromatase inhibitor, it reduces local estrogen production that feeds endometriotic lesions. A pilot study (N=75) in Reproductive BioMedicine Online found that letrozole combined with laparoscopic lesion excision produced higher pregnancy rates than excision alone in endometriosis patients (42.1% vs. 26.3% per cycle) [16].

When IVF Becomes the Path Forward

In vitro fertilization bypasses many of the obstacles created by both conditions. It circumvents anovulation, reduces dependence on tubal patency, and allows embryo selection. For dual-diagnosis patients who have not conceived after ovulation induction and/or surgery, IVF offers the highest per-cycle probability of pregnancy. ACOG recommends consideration of IVF after 3 to 6 failed ovulation induction cycles in PCOS or after failed surgical management in endometriosis [9].

Mental Health and Quality of Life

The psychological burden of carrying two chronic reproductive diagnoses is substantial but under-studied. A 2022 cross-sectional survey in Human Reproduction Open (N=1,423) reported that women with both PCOS and endometriosis had significantly higher anxiety and depression scores compared to women with either condition alone (PHQ-9 mean 12.4 vs. 8.7 for PCOS alone vs. 9.2 for endometriosis alone, P<0.001) [17].

Pain, Body Image, and Diagnostic Fatigue

PCOS-related concerns often center on weight, acne, hair growth, and metabolic risk. Endometriosis-related concerns center on pain, fatigue, and functional limitations. Carrying both means managing symptoms across body systems simultaneously. The average diagnostic delay for endometriosis (7 to 10 years from symptom onset per the World Endometriosis Research Foundation) [18] means many patients spend years being told their pain is normal or attributable to their already-diagnosed PCOS.

Screening Recommendations

The 2023 PCOS guideline recommends routine screening for anxiety and depression using validated tools (PHQ-9, GAD-7) at diagnosis and periodically thereafter [5]. No equivalent formal guideline exists for endometriosis, but the clinical rationale for screening is equally strong, particularly in dual-diagnosis patients.

What to Ask Your Provider

If you have PCOS and suspect endometriosis (or vice versa), specific questions can move the conversation forward. Ask whether your pelvic pain pattern has been formally evaluated beyond your existing diagnosis. Ask whether an androgen panel and metabolic workup have been completed if you carry only an endometriosis diagnosis. Ask about a trial of empiric hormonal therapy targeting both conditions before committing to diagnostic laparoscopy.

The Endocrine Society's 2023 guideline states that "clinicians should maintain a low threshold for investigating co-existing conditions in patients with PCOS, particularly when symptoms are discordant with the expected clinical picture" [5]. That language applies directly to pain symptoms that PCOS alone does not explain.

Patients with confirmed dual diagnosis should receive coordinated care. An endocrinologist or reproductive endocrinologist managing the PCOS component should communicate with the gynecologic surgeon managing the endometriosis component. Treatment decisions for one condition affect the other, and fragmented care leads to conflicting recommendations.